Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major myocardial infarction markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.94% during 2024-2034.
The myocardial infarction market has been comprehensively analyzed in IMARC's new report titled "Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myocardial infarction, also known as a heart attack, is a life-threatening condition that develops when blood flow to the heart muscle is blocked, leading to tissue damage. The most prominent symptom is severe and persistent chest pain or discomfort that may spread to the arms, neck, jaw, or back. This pain is often accompanied by shortness of breath, sweating, nausea, lightheadedness, and an overwhelming sense of anxiety. Some patients may also experience unusual fatigue, heart palpitations, a feeling of indigestion, etc. The diagnosis of myocardial infarction involves a combination of medical history evaluation, physical examination, and diagnostic tests. The healthcare provider will inquire about the patient's symptoms, risk factors, and medical history. During the physical exam, they may monitor heart and lung conditions, check blood pressure, and assess overall signs of distress. Various diagnostic procedures, such as an electrocardiogram (ECG), blood tests, imaging techniques like echocardiography or coronary angiography, etc., are also performed to confirm the diagnosis. These tests help to identify abnormal changes in the heart's electrical activity, detect the presence of certain enzymes released during a heart attack, and visualize the blood flow to the heart.
The increasing cases of coronary artery diseases in which plaque builds up on the inner walls of the arteries and reduces blood flow to the heart muscle are primarily driving the myocardial infarction market. Furthermore, the rising prevalence of various associated risk factors, including high cholesterol levels, excessive alcohol consumption, smoking, lack of physical activity, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of beta-blockers, such as metoprolol, bisoprolol, carvedilol, etc., since they decrease the workload on the heart by slowing the heart rate and lowering blood pressure, thereby promoting healing and reducing the likelihood of future heart attacks, is also creating a positive outlook for the market. Moreover, the increasing utilization of radial access surgery on account of its several associated benefits, including a lower risk of access-site complications, better patient comfort, early mobilization, etc., is further augmenting the market growth. Apart from this, the escalating demand for drug-eluting stents, which have drastically reduced the incidence of restenosis and enhanced the effectiveness of stent placement, is expected to drive the myocardial infarction market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the myocardial infarction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myocardial infarction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myocardial infarction market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the myocardial infarction market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the myocardial infarction market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current myocardial infarction marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the myocardial infarction market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the myocardial infarction market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the myocardial infarction market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of myocardial infarction across the seven major markets?
What is the number of prevalent cases (2018-2034) of myocardial infarction by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of myocardial infarction by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of myocardial infarction by type across the seven major markets?
How many patients are diagnosed (2018-2034) with myocardial infarction across the seven major markets?
What is the size of the myocardial infarction patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of myocardial infarction?
What will be the growth rate of patients across the seven major markets?
Myocardial Infarction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for myocardial infarction drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myocardial infarction market?
What are the key regulatory events related to the myocardial infarction market?
What is the structure of clinical trial landscape by status related to the myocardial infarction market?
What is the structure of clinical trial landscape by phase related to the myocardial infarction market?
What is the structure of clinical trial landscape by route of administration related to the myocardial infarction market?
The myocardial infarction market has been comprehensively analyzed in IMARC's new report titled "Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myocardial infarction, also known as a heart attack, is a life-threatening condition that develops when blood flow to the heart muscle is blocked, leading to tissue damage. The most prominent symptom is severe and persistent chest pain or discomfort that may spread to the arms, neck, jaw, or back. This pain is often accompanied by shortness of breath, sweating, nausea, lightheadedness, and an overwhelming sense of anxiety. Some patients may also experience unusual fatigue, heart palpitations, a feeling of indigestion, etc. The diagnosis of myocardial infarction involves a combination of medical history evaluation, physical examination, and diagnostic tests. The healthcare provider will inquire about the patient's symptoms, risk factors, and medical history. During the physical exam, they may monitor heart and lung conditions, check blood pressure, and assess overall signs of distress. Various diagnostic procedures, such as an electrocardiogram (ECG), blood tests, imaging techniques like echocardiography or coronary angiography, etc., are also performed to confirm the diagnosis. These tests help to identify abnormal changes in the heart's electrical activity, detect the presence of certain enzymes released during a heart attack, and visualize the blood flow to the heart.
The increasing cases of coronary artery diseases in which plaque builds up on the inner walls of the arteries and reduces blood flow to the heart muscle are primarily driving the myocardial infarction market. Furthermore, the rising prevalence of various associated risk factors, including high cholesterol levels, excessive alcohol consumption, smoking, lack of physical activity, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of beta-blockers, such as metoprolol, bisoprolol, carvedilol, etc., since they decrease the workload on the heart by slowing the heart rate and lowering blood pressure, thereby promoting healing and reducing the likelihood of future heart attacks, is also creating a positive outlook for the market. Moreover, the increasing utilization of radial access surgery on account of its several associated benefits, including a lower risk of access-site complications, better patient comfort, early mobilization, etc., is further augmenting the market growth. Apart from this, the escalating demand for drug-eluting stents, which have drastically reduced the incidence of restenosis and enhanced the effectiveness of stent placement, is expected to drive the myocardial infarction market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the myocardial infarction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myocardial infarction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myocardial infarction market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the myocardial infarction market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the myocardial infarction market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current myocardial infarction marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the myocardial infarction market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the myocardial infarction market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the myocardial infarction market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of myocardial infarction across the seven major markets?
What is the number of prevalent cases (2018-2034) of myocardial infarction by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of myocardial infarction by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of myocardial infarction by type across the seven major markets?
How many patients are diagnosed (2018-2034) with myocardial infarction across the seven major markets?
What is the size of the myocardial infarction patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of myocardial infarction?
What will be the growth rate of patients across the seven major markets?
Myocardial Infarction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for myocardial infarction drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myocardial infarction market?
What are the key regulatory events related to the myocardial infarction market?
What is the structure of clinical trial landscape by status related to the myocardial infarction market?
What is the structure of clinical trial landscape by phase related to the myocardial infarction market?
What is the structure of clinical trial landscape by route of administration related to the myocardial infarction market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYOCARDIAL INFARCTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYOCARDIAL INFARCTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYOCARDIAL INFARCTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 MYOCARDIAL INFARCTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYOCARDIAL INFARCTION - UNMET NEEDS
10 MYOCARDIAL INFARCTION - KEY ENDPOINTS OF TREATMENT
11 MYOCARDIAL INFARCTION - MARKETED PRODUCTS
11.1 List of Myocardial Infarction Marketed Drugs Across the Top 7 Markets
11.1.1 Lovenox (Enoxaparin sodium) - Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Retavase (Reteplase) - Chiesi USA, Inc
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Repatha (Evolocumab) - Amgen
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 TNKase (Tenecteplase) - Genentech
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Plavix (Clopidogrel) - Sanofi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MYOCARDIAL INFARCTION - PIPELINE DRUGS
12.1 List of Myocardial Infarction Pipeline Drugs Across the Top 7 Markets
12.1.1 Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 GNR-060 - GENERIUM Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 FDY-5301 - Faraday Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Dutogliptin Tartrate - Recardio
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Zalunfiban - Celecor Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MYOCARDIAL INFARCTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYOCARDIAL INFARCTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYOCARDIAL INFARCTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Myocardial Infarction - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Myocardial Infarction - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Myocardial Infarction - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Myocardial Infarction - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Myocardial Infarction - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Myocardial Infarction - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Myocardial Infarction - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Myocardial Infarction - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Myocardial Infarction - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Myocardial Infarction - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Myocardial Infarction - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Myocardial Infarction - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Myocardial Infarction - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Myocardial Infarction - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Myocardial Infarction - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Myocardial Infarction - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Myocardial Infarction - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Myocardial Infarction - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Myocardial Infarction - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Myocardial Infarction - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Myocardial Infarction - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Myocardial Infarction - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Myocardial Infarction - Access and Reimbursement Overview
16 MYOCARDIAL INFARCTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYOCARDIAL INFARCTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYOCARDIAL INFARCTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYOCARDIAL INFARCTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYOCARDIAL INFARCTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYOCARDIAL INFARCTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 MYOCARDIAL INFARCTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYOCARDIAL INFARCTION - UNMET NEEDS
10 MYOCARDIAL INFARCTION - KEY ENDPOINTS OF TREATMENT
11 MYOCARDIAL INFARCTION - MARKETED PRODUCTS
11.1 List of Myocardial Infarction Marketed Drugs Across the Top 7 Markets
11.1.1 Lovenox (Enoxaparin sodium) - Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Retavase (Reteplase) - Chiesi USA, Inc
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Repatha (Evolocumab) - Amgen
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 TNKase (Tenecteplase) - Genentech
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Plavix (Clopidogrel) - Sanofi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MYOCARDIAL INFARCTION - PIPELINE DRUGS
12.1 List of Myocardial Infarction Pipeline Drugs Across the Top 7 Markets
12.1.1 Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 GNR-060 - GENERIUM Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 FDY-5301 - Faraday Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Dutogliptin Tartrate - Recardio
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Zalunfiban - Celecor Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MYOCARDIAL INFARCTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYOCARDIAL INFARCTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYOCARDIAL INFARCTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Myocardial Infarction - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Myocardial Infarction - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Myocardial Infarction - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Myocardial Infarction - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Myocardial Infarction - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Myocardial Infarction - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Myocardial Infarction - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Myocardial Infarction - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Myocardial Infarction - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Myocardial Infarction - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Myocardial Infarction - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Myocardial Infarction - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Myocardial Infarction - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Myocardial Infarction - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Myocardial Infarction - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Myocardial Infarction - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Myocardial Infarction - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Myocardial Infarction - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Myocardial Infarction - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Myocardial Infarction - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Myocardial Infarction - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Myocardial Infarction - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Myocardial Infarction - Access and Reimbursement Overview
16 MYOCARDIAL INFARCTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYOCARDIAL INFARCTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYOCARDIAL INFARCTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
